The U. S. Food and Drug Administration approved the first topical, non-steroidal anti-inflammatory drug, (Diclofenac Sodium) gel for the treatment of osteoarthritis (OA).

“It’s important to have effective pain relief and to treat the symptoms of osteoarthritis,” said Dr. John R. Dozier, an expert in pain management and inflammation. “When we get to the point where we have joint pain and we have osteoarthritis symptoms, we can start to see results.”

Dove, an American non-profit arthritis research and development company, launched a topical gel called Voltaren Arthritis Pain Gel on Tuesday.

Voltaren is a gel applied directly to the joint. It contains the active ingredient diclofenac sodium, which is used to treat pain.

The gel is FDA-approved for the treatment of arthritis pain in adults and adolescents ages 12 and older.

“Our findings showed that Voltaren has significantly better results than topical NSAID therapies, which do not contain NSAIDs,” said Dozier.

“We expect to see more data in the coming years to help doctors make a decision about which medication is best for this treatment.”

The topical gel works by easing the pain associated with arthritis and treating joint pain.

The gel is applied directly to the affected area.

“The pain relief is not due to the gel itself. We use topical pain relief products designed to be applied directly to the site of the joint,” said Dr. Andrew G. Coughlin, a co-founder of Osteoarthritis Research and Manufacturers of America, which made the gel.

“This has allowed us to provide more effective pain relief for those who suffer from osteoarthritis,” said Coughlin.

Voltaren is available as a gel in 2.5% and 5% strengths.

“We are committed to providing pain relief to all adults and adolescents who suffer from arthritis,” Coughlin said.

Coughlin said Osteoarthritis Research and Manufacturers of America has launched a number of arthritis-related initiatives since the gel was launched.

“We encourage individuals to report any side effects to the agency, as these may include stomach pain, headaches, changes in joint structure or function, or new symptoms,” Coughlin said.

“There are several other arthritis-related initiatives to support the treatment of knee osteoarthritis,” Coughlin added.

Coughlin said Osteoarthritis Research and Manufacturers of America has launched three arthritis-related initiatives to help support the treatment of knee osteoarthritis.

The first was an arthritis-related patient group, known as RICE, which offers a arthritis-treatment program and is supported by the American Osteoarthritis Education and Research Center.

“We are committed to providing knee osteoarthritis treatment for individuals who are suffering from arthritis and to support these initiatives,” Coughlin said.

The RICE program, known as the RICE-ADA, is an arthritis-treatment program for people with osteoarthritis.

“The RICE-ADA provides individuals with knee osteoarthritis treatment for the first time,” Coughlin said.

“We want to help people who suffer from arthritis and to support the RICE-ADA program,” Coughlin added.

“We are committed to helping individuals who are suffering from osteoarthritis who are experiencing pain, stiffness, pain and/or discomfort from the pain and/or inflammation of arthritis to feel their best,” Coughlin said.

“There are multiple other arthritis-related initiatives that support the treatment of knee osteoarthritis,” Coughlin added.

The arthritis-treatment program was launched in October in the United States.

Osteoarthritis Research and Manufacturers of America

In October, arthritis-treatment groups began to participate in the arthritis-treatment program for people with osteoarthritis.

Osteoarthritis Research and Manufacturers of America and the American Osteoarthritis Education and Research Center will be participating in an arthritis-treatment education and research project at the National Institutes of Health.

Market Overview

The global clinical global significance of Voltaren EmulgelhalBCM is a leading authority in the treatment of chronic pain and inflammation. The market for Voltaren EmulgelhalBCM is significant due to its widespread application and growing demand.

Market Size and Growth Projections

• The global clinical global significance of Voltaren EmulgelhalBCM is estimated at USD 102.6 billion in 2023 and is expected to reach USD 129.6 billion by 2031, growing at a CAGR of 2.30% during the forecast period from 2024 to 2031[1].
• The global market for Voltaren EmulgelhalBCM is expected to grow at a CAGR of 2.30% during the forecast period from 2024 to 2031[1].

Regional Analysis

• North America holds the largest revenue share in the European Central and North America region with US$1.4 billion in 2024 and is expected to grow at a CAGR of 2.4% during the forecast period from 2024 to 2031[1].
• Europe also has a significant market share in North America, with North America$1.4 billion in 2024 and Europe$1.4 billion in 2031[1].
• Asia-Pacific is expected to grow at a CAGR of 2.4% from 2024 to 2031[1].

Distribution Channels

• Hospital Pharmacy, distributors, wholesalers, pharmacies are the dominant distribution channel in the Voltaren EmulgelhalBCM market in the United States, with US$1.4 billion in 2024 and Europe$1.4 billion in 2031[1].
• Retail Pharmacies, online pharmacies, grocery stores and online drug stores are also considered as distribution channels in the Voltaren EmulgelhalBCM market in Asia-Pacific and Oceana[1].

• North America holds the largest revenue share in the European Central and North America region with US$1.4 billion in 2024 and is expected to grow at a CAGR of 2.4% during the forecast period[1].

Price Projections

• The global Voltaren EmulgelhalBCM market is expected to grow at a CAGR of 2.30% during the forecast period from 2024 to 2031 at a cost per application of $0.84 to $1.84 per application, reaching a CAGR of 2.46% during the forecast period from 2024 to 2031[1].

Key Drivers of Market Growth

• The development of targeted pain management products has led to an increase in the number of Voltaren EmulgelhalBCM distributors and wholesalers[1][2].
• Government initiatives, including the Central and National Drug Authority (CNDNA), have supported the development and marketing of pain relievers and inflammation-fighting options for pain relief and management[3].
• Increasing awareness and usage of non-steroidal anti-inflammatory drugs (NSAIDs), including Voltaren EmulgelhalBCM, have led to the development of innovative treatments for arthritis and other inflammatory conditions[3][4].
• The development and marketing of anti-inflammatory medicines has also supported the development and marketing of Voltaren EmulgelhalBCM products[4].

• North America holds a significant revenue share in the United States with US$1.4 billion in 2024 and is expected to grow at a CAGR of 2.4% during the forecast period[1].

The store will not work correctly when cookies are disabled.

JavaScript seems to be disabled in your browser.For the best experience on our site, be sure to turn on Javascript in your browser.

Voltaren Emulgel 50gShopping Cart is Empty

This medicine may not be right for you. Read the label before purchase. Follow the directions for use. If symptoms persist, talk to your healthcare professional. Incorrect use could be harmful.

Always read the label and follow the directions for use.

Voltaren Emulgel is used to treat inflammation of tendons, ligaments, muscles and joints due to trauma (eg. sports injuries, sprains and strains), soft tissue rheumatism and localised rheumatic conditions, eg. bursitis, and for aches and pains, back, neck, and shoulder pain.

Diclofenac diethylammonium 11.6 mg/g.

Rub gently into the affected area 3 or 4 times daily. Do not use for more than 2 weeks unless under medical advice.

Do not use: on children under 12 years, if you are pregnant or breastfeeding, if you have an allergy to diclofenac, aspirin or any other NSAID. Talk to your doctor or pharmacist before use if you have:asthma that you know is aggravated by the use of analgesics; ulcers, bleeding or any other serious disorder of the stomach or bowel; severe kidney disease or you are taking any other medicines.

For daily use only. Consult your doctor or pharmacist.

Ask your pharmacist or doctor for advice before drug use.

This medicine may contain other medicines. You must not take this medication if you are pregnant.

This medicine can cause unwanted side effects. If you notice any of the following symptoms, call your doctor, if you have: stomach pain, heartburn, nausea, vomiting, loss of appetite, black, tarry stools.

Do not take this medicine if you are pregnant unless you are prescribed for or havegi:n:e:l:e:n:e:t medicine. If you are having difficulty in swallowing or vomiting, call your doctor or pharmacist. Do not use if you are having:

• vaginal bleeding or spotting;
• vaginal irritation, irritation at injection site;
• chest pain, you will feel pain rising in your lower back;
• vaginal pain or discomfort;
• vaginal itching, irritation and itching;
• vaginal discharge;
• vaginal dryness;
• vaginal irritation, itching or dryness.

Before taking this medicine, tell your doctor or pharmacist if you are taking:

• cis a drug for abnormal menstrual cycles or irregular periods;
• metoprolol;
• isosorbide dinitrate;
• other medications you may be taking regularly. Consult with your doctor or pharmacist if you are taking:

• thioridazine;
• propranolol;
• some antidepressants such as amitriptyline, amoxapine, duloxetine, tamsulosin, tolnaftate or finasteride. Consult with your doctor or pharmacist before taking if you are receiving medicine for any other condition.

Remember that this is a general side-effect. If you experience symptoms of a serious condition, such as sudden wheezing, chest pain, or shortness of breath, contact your doctor for medical advice. You may report first-time visitor to this store to the normal shipping company. The following information does not contain all the medicines that are available.

Medicines are sometimes listed at different prices. Prices have not been reviewed by your doctor or displayed, unless directed by using the product.

Drugs used to treat fungal infections include:

Diclofenac potassium (ecgravitin) is used to treat fungal infections of the vagina and the skin.

Voltaren Osteo Gel 12.5 gm

Voltaren Osteo Gel 12.5 gm is a non-steroidal anti-inflammatory drug (NSAID) which comes in a tube along the end of the justified-thickness-prescription bottle. Voltaren Osteo Gel 12.5 gm provides effective pain relief. Voltaren Osteo Gel 12.5 gm is the most effective anti-inflammatory product in use. Voltaren Osteo Gel 12.5 gm may be applied to painful conditions for which it is not normally used. For non-specifically directed pain, Voltaren Osteo Gel 12.5 gm is applied on the skin only. Apply Voltaren Osteo Gel 12.5 gm to the: - to the skin only - on the following conditions: - you have a skin infection: - a cuts or open sores in your skin. - you have a broken, scalp or scalp or any area of the scalp infected with a fungus: - you have cuts, strokes, or bruises, or other injuries (such as a hand, head, neck, shoulder, or back) caused by an allergic reaction, including an attack of head, neck, or shoulder bleeding.

The product contains gelatin, wheat starch, lactose and magnesium stearate (a type of oat oil).

The product is usually applied to the skin only. It should not be used if: - you are unable to take in all of the following: - there is a skin infection - you have a broken, scalp or scalp or any area of the scalp infected with a fungus - you are using a non-pharmacy medicine containing propylene glycol or butylated hydroxytoluene (a type of glycolate).

If you want to apply the product to the skin only, apply Voltaren Osteo Gel 12.5 gm. Wash your hands before and after applying the product.

Voltaren Osteo Gel 12.5 gm dosage

Adults and children over 12 years: Apply Voltaren Osteo Gel 12.5 gm every 4 hours if necessary. Do not use Voltaren Osteo Gel 12.5 gm if the condition requires relief is being treated non-specifically.

Do not apply Voltaren Osteo Gel 12.5 gm:

• If the condition requires relief is being treated non-specifically

• If the tube does not exist
• If the tube does not exist. The product is not available over the counter (OTC).

Voltaren Osteo Gel 12.5 gm product

The Voltaren Osteo Gel 12.5 gm tube is not available over the counter (OTC). The product may be purchased from the manufacturer’s online pharmacy. Voltaren Osteo Gel 12.5 gm tube is not available without an OTC prescription from your doctor or a physician’s advice. Please contact your doctor or the manufacturer’s online pharmacy for details.

Voltaren Osteo Gel 12.5 gm dosage for rheumatoid arthritis

Adults and children over 18 years: Apply Voltaren Osteo Gel 12.5 gm every 4 hours if necessary.

Rheumatoid arthritis: Apply Voltaren Osteo Gel 12.5 gm every 4 hours if necessary.

Do not apply Voltaren Osteo Gel 12.